{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:07:14Z","timestamp":1793830034974,"version":"4.6.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T00:00:00Z","timestamp":1383177600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s12020-013-0083-z","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T20:33:06Z","timestamp":1383165186000},"page":"370-381","source":"Crossref","is-referenced-by-count":61,"title":["Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis"],"prefix":"10.1007","volume":"45","author":[{"given":"Annie-Claude M.","family":"Lassemillante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhail A. R.","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia R. L.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,31]]},"reference":[{"issue":"2","key":"83_CR1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpgasthep1332","volume":"6","author":"WP Harris","year":"2009","unstructured":"W.P. Harris, E.A. Mostaghel, P.S. Nelson, B. Montgomery, Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Oncol. 6(2), 76\u201385 (2009). doi: 10.1038\/ncpuro1296","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"2","key":"83_CR2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"N. Sharifi, J.L. Gulley, W.L. Dahut, Androgen deprivation therapy for prostate cancer. JAMA 294(2), 238\u2013244 (2005). doi: 10.1001\/jama.294.2.238","journal-title":"JAMA"},{"issue":"6","key":"83_CR3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5694\/j.1326-5377.2011.tb02979.x","volume":"194","author":"M Grossmann","year":"2011","unstructured":"M. Grossmann, E.J. Hamilton, C. Gilfillan, D. Bolton, D.L. Joon, J.D. Zajac, Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med. J. Aust. 194(6), 301\u2013306 (2011)","journal-title":"Med. J. Aust."},{"issue":"6","key":"83_CR4","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0022-5347(05)67533-7","volume":"163","author":"HW Herr","year":"2000","unstructured":"H.W. Herr, M. O\u2019Sullivan, Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J. Urol. 163(6), 1743\u20131746 (2000). doi: 10.1016\/S0022-5347(05)67533-7","journal-title":"J. Urol."},{"issue":"11","key":"83_CR5","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","volume":"115","author":"LG Taylor","year":"2009","unstructured":"L.G. Taylor, S.E. Canfield, X.L. Du, Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115(11), 2388\u20132399 (2009). doi: 10.1002\/cncr.24283","journal-title":"Cancer"},{"issue":"1","key":"83_CR6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0984","volume":"5","author":"CS Higano","year":"2008","unstructured":"C.S. Higano, Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat. Clin. Pract. Oncol. 5(1), 24\u201334 (2008)","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"5","key":"83_CR7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/13697137.2012.658110","volume":"15","author":"V Seifert-Klauss","year":"2012","unstructured":"V. Seifert-Klauss, S. Fillenberg, H. Schneider, P. Luppa, D. Mueller, M. Kiechle, Bone loss in premenopausal, perimenopausal and postmenopausal women: results of a prospective observational study over 9\u00a0years. Climacteric 15(5), 433\u2013440 (2012). doi: 10.3109\/13697137.2012.658110","journal-title":"Climacteric"},{"issue":"5","key":"83_CR8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1359\/jbmr.2005.20.5.886","volume":"20","author":"LJ Melton","year":"2005","unstructured":"L.J. Melton, E.A. Chrischilles, C. Cooper, A.W. Lane, B.L. Riggs, How many women have osteoporosis? J. Bone Miner. Res. 20(5), 886\u2013892 (2005). doi: 10.1359\/jbmr.2005.20.5.886","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"83_CR9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2490-10-9","volume":"10","author":"AS Neto","year":"2010","unstructured":"A.S. Neto, M. Tobias-Machado, M.A. Esteves, M.D. Senra, M.L. Wroclawski, F.L. Fonseca, R.B. dos Reis, A.C. Pompeo, A. Del Giglio, A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol. 10(1), 9 (2010). doi: 10.1186\/1471-2490-10-9","journal-title":"BMC Urol."},{"key":"83_CR10","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780195326543.001.0001","volume-title":"Systematic reviews and meta-analysis. Pocket guides to social work research methods","author":"JH Littell","year":"2008","unstructured":"J.H. Littell, J. Corcoran, V.K. Pillai, Systematic reviews and meta-analysis. Pocket guides to social work research methods (Oxford University Press, Oxford, 2008)"},{"issue":"10","key":"83_CR11","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62(10), 1006\u20131012 (2009). doi: 10.1016\/j.jclinepi.2009.06.005","journal-title":"J. Clin. Epidemiol."},{"issue":"9","key":"83_CR12","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","volume":"65","author":"D Hoy","year":"2012","unstructured":"D. Hoy, P. Brooks, A. Woolf, F. Blyth, L. March, C. Bain, P. Baker, E. Smith, R. Buchbinder, Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J. Clin. Epidemiol. 65(9), 934\u2013939 (2012). doi: 10.1016\/j.jclinepi.2011.11.014","journal-title":"J. Clin. Epidemiol."},{"issue":"11","key":"83_CR13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","volume":"53","author":"JAC Sterne","year":"2000","unstructured":"J.A.C. Sterne, D. Gavaghan, M. Egger, Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J. Clin. Epidemiol. 53(11), 1119\u20131129 (2000). doi: 10.1016\/s0895-4356(00)00242-0","journal-title":"J. Clin. Epidemiol."},{"issue":"3","key":"83_CR14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1467-985X.2009.00629.x","volume":"173","author":"JL Peters","year":"2010","unstructured":"J.L. Peters, A.J. Sutton, D.R. Jones, K.R. Abrams, L. Rushton, S.G. Moreno, Assessing publication bias in meta-analyses in the presence of between-study heterogeneity. J. R. Stat. Soc. 173(3), 575\u2013591 (2010). doi: 10.1111\/j.1467-985X.2009.00629.x","journal-title":"J. R. Stat. Soc."},{"issue":"8","key":"83_CR15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"J.A. Kanis, L.J. Melton, C. Christiansen, C.C. Johnston, N. Khaltaev, The diagnosis of osteoporosis. J. Bone Miner. Res. 9(8), 1137\u20131141 (1994). doi: 10.1002\/jbmr.5650090802","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"83_CR16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/oxfordjournals.aje.a009981","volume":"150","author":"B Takkouche","year":"1999","unstructured":"B. Takkouche, C. Cadarso-Su\u00e1rez, D. Spiegelman, Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am. J. Epidemiol. 150(2), 206\u2013215 (1999)","journal-title":"Am. J. Epidemiol."},{"issue":"12","key":"83_CR17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N","volume":"15","author":"R Dersimonian","year":"1996","unstructured":"R. Dersimonian, Meta-analysis in the design and monitoring of clinical trials. Stat. Med. 15(12), 1237\u20131248 (1996). doi: 10.1002\/(sici)1097-0258(19960630)15:12<1237:aid-sim301>3.0.co;2-n","journal-title":"Stat. Med."},{"issue":"1","key":"83_CR18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/EDE.0b013e31815c24e7","volume":"19","author":"SA Doi","year":"2008","unstructured":"S.A. Doi, L. Thalib, A quality-effects model for meta-analysis. Epidemiology 19(1), 94\u2013100 (2008). doi: 10.1097\/EDE.0b013e31815c24e7","journal-title":"Epidemiology"},{"issue":"2","key":"83_CR19","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cct.2010.12.006","volume":"32","author":"SAR Doi","year":"2011","unstructured":"S.A.R. Doi, J.J. Barendregt, E.L. Mozurkewich, Meta-analysis of heterogeneous clinical trials: an empirical example. Contemp. Clin. Trials 32(2), 288\u2013298 (2011). doi: 10.1016\/j.cct.2010.12.006","journal-title":"Contemp. Clin. Trials"},{"issue":"7","key":"83_CR20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/sim.2639","volume":"26","author":"S Senn","year":"2007","unstructured":"S. Senn, Trying to be precise about vagueness. Stat. Med. 26(7), 1417\u20131430 (2007). doi: 10.1002\/sim.2639","journal-title":"Stat. Med."},{"issue":"3","key":"83_CR21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jocd.2012.01.010","volume":"15","author":"PR Sieber","year":"2012","unstructured":"P.R. Sieber, F.M. Rommel, C.G. Theodoran, P.J. Russinko, C.A. Woodward, L. Schimke, The role of distal third radius dual energy X-ray absorptiometry (DXA) and central DXA in evaluating for osteopenia and osteoporosis in men receiving androgen deprivation therapy for prostate cancer. J. Clin. Densitom. 15(3), 351\u2013354 (2012). doi: 10.1016\/j.jocd.2012.01.010","journal-title":"J. Clin. Densitom."},{"issue":"15","key":"83_CR22","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2011.38.3745","volume":"30","author":"EY Yu","year":"2012","unstructured":"E.Y. Yu, K.F. Kuo, R. Gulati, S. Chen, T.E. Gambol, S.P. Hall, P.Y. Jiang, P. Pitzel, C.S. Higano, Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. J. Clin. Oncol. 30(15), 1864\u20131870 (2012). doi: 10.1200\/jco.2011.38.3745","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"83_CR23","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1677\/ERC-08-0116","volume":"15","author":"W Wang","year":"2008","unstructured":"W. Wang, T. Yuasa, N. Tsuchiya, S. Maita, T. Kumazawa, T. Inoue, M. Saito, Z. Ma, T. Obara, H. Tsuruta, S. Satoh, T. Habuchi, Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr. Relat Cancer 15(4), 943\u2013952 (2008). doi: 10.1677\/erc-08-0116","journal-title":"Endocr. Relat Cancer"},{"issue":"4","key":"83_CR24","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/j.juro.2010.02.1615","volume":"183","author":"T Yuasa","year":"2010","unstructured":"T. Yuasa, S. Maita, N. Tsuchiya, S. Takahashi, K. Hatake, I. Fukui, T. Habuchi, Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. J. Urol. 183(4), e335 (2010). doi: 10.1016\/j.urology.2009.10.075","journal-title":"J. Urol."},{"issue":"1","key":"83_CR25","first-page":"75","volume":"6","author":"JH Deng","year":"2004","unstructured":"J.H. Deng, L.P. Yang, L.S. Wang, D.F. Zhou, Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients. Asian J. Androl. 6(1), 75\u201377 (2004)","journal-title":"Asian J. Androl."},{"issue":"6","key":"83_CR26","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1464-410X.2009.08458.x","volume":"104","author":"NA Spry","year":"2009","unstructured":"N.A. Spry, D.A. Galvao, R. Davies, S. La Bianca, D. Joseph, A. Davidson, R. Prince, Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int. 104(6), 806\u2013812 (2009). doi: 10.1111\/j.1464-410X.2009.08458.x","journal-title":"BJU Int."},{"issue":"1","key":"83_CR27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.urology.2005.07.017","volume":"67","author":"JM Bruder","year":"2006","unstructured":"J.M. Bruder, J.Z. Ma, J.W. Basler, M.D. Welch, Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 67(1), 152\u2013155 (2006). doi: 10.1016\/j.urology.2005.07.017","journal-title":"Urology"},{"issue":"10","key":"83_CR28","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.10967","volume":"95","author":"Z Chen","year":"2002","unstructured":"Z. Chen, M. Maricic, P. Nguyen, F.R. Ahmann, R. Bruhn, B.L. Dalkin, Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 95(10), 2136\u20132144 (2002). doi: 10.1002\/cncr.10967","journal-title":"Cancer"},{"issue":"4","key":"83_CR29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(99)00301-5","volume":"54","author":"JT Wei","year":"1999","unstructured":"J.T. Wei, M. Gross, C.A. Jaffe, K. Gravlin, M. Lahaie, G.J. Faerber, K.A. Cooney, Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54(4), 607\u2013611 (1999). doi: 10.1016\/S0090-4295(99)00301-5","journal-title":"Urology"},{"issue":"2","key":"83_CR30","first-page":"589","volume":"29","author":"MM Bernat","year":"2005","unstructured":"M.M. Bernat, J. Pasini, Z. Marekovic, Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy. Coll. Antropol. 29(2), 589\u2013591 (2005)","journal-title":"Coll. Antropol."},{"issue":"3","key":"83_CR31","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","volume":"69","author":"J Morote","year":"2007","unstructured":"J. Morote, J.P. Morin, A. Orsola, J.M. Abascal, C. Salvador, E. Trilla, C.X. Raventos, L. Cecchini, G. Encabo, J. Reventos, Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69(3), 500\u2013504 (2007). doi: 10.1016\/j.urology.2006.11.002","journal-title":"Urology"},{"issue":"3","key":"83_CR32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.pcan.4500520","volume":"4","author":"JL Peters","year":"2001","unstructured":"J.L. Peters, A. Fairney, P. Kyd, A. Patel, S. Rogers, J.J. Webster, J.A. Vale, R.O.N. Witherow, Bone loss associated with the use of LHRH agonists in prostate cancer. Prostate Cancer Prostatic Dis. 4(3), 161\u2013166 (2001). doi: 10.1038\/sj.pcan.4500520","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"4","key":"83_CR33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1464-410X.2006.06695.x","volume":"99","author":"J Planas","year":"2007","unstructured":"J. Planas, J. Morote, A. Orsola, C. Salvador, E. Trilla, L. Cecchini, C.X. Raventos, J.P. Morin, The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int. 99(4), 812\u2013815 (2007). doi: 10.1111\/j.1464-410X.2006.06695.x","journal-title":"BJU Int."},{"issue":"11","key":"83_CR34","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1359\/jbmr.1997.12.11.1761","volume":"12","author":"AC Looker","year":"1997","unstructured":"A.C. Looker, E.S. Orwoll, C.C. Johnston, R.L. Lindsay, H.W. Wahner, W.L. Dunn, M.S. Calvo, T.B. Harris, S.P. Heyse, Prevalence of low femoral bone density in older US adults from NHANES III. J. Bone Miner. Res. 12(11), 1761\u20131768 (1997). doi: 10.1359\/jbmr.1997.12.11.1761","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"83_CR35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"J.E. Brown, R.J. Cook, P. Major, A. Lipton, F. Saad, M. Smith, K.-A. Lee, M. Zheng, Y.-J. Hei, R.E. Coleman, Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl Cancer Inst. 97(1), 59\u201369 (2005). doi: 10.1093\/jnci\/dji002","journal-title":"J. Natl Cancer Inst."},{"issue":"9","key":"83_CR36","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1172\/JCI31791","volume":"117","author":"RS Taichman","year":"2007","unstructured":"R.S. Taichman, R.D. Loberg, R. Mehra, K.J. Pienta, The evolving biology and treatment of prostate cancer. J. Clin. Invest. 117(9), 2351\u20132361 (2007). doi: 10.1172\/JCI31791","journal-title":"J. Clin. Invest."},{"issue":"1","key":"83_CR37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrc1528","volume":"5","author":"CJ Logothetis","year":"2005","unstructured":"C.J. Logothetis, S.H. Lin, Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 5(1), 21\u201328 (2005). doi: 10.1038\/nrc1528","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"83_CR38","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jcb.10662","volume":"91","author":"ET Keller","year":"2004","unstructured":"E.T. Keller, J. Brown, Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J. Cell. Biochem. 91(4), 718\u2013729 (2004). doi: 10.1002\/jcb.10662","journal-title":"J. Cell. Biochem."},{"issue":"22","key":"83_CR39","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","volume":"23","author":"RE Coleman","year":"2005","unstructured":"R.E. Coleman, P. Major, A. Lipton, J.E. Brown, K.-A. Lee, M. Smith, F. Saad, M. Zheng, Y.J. Hei, J. Seaman, R. Cook, Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 23(22), 4925\u20134935 (2005). doi: 10.1200\/jco.2005.06.091","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"83_CR40","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/annonc\/mdq037","volume":"21","author":"S Rajpar","year":"2010","unstructured":"S. Rajpar, C. Massard, A. Laplanche, E. Tournay, M. Gross-Goupil, Y. Loriot, M. Di Palma, A. Bossi, B. Escudier, A. Chauchereau, K. Fizazi, Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann. Oncol. 21(9), 1864\u20131869 (2010). doi: 10.1093\/annonc\/mdq037","journal-title":"Ann. Oncol."},{"issue":"2","key":"83_CR41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jcb.22970","volume":"112","author":"SA Krum","year":"2011","unstructured":"S.A. Krum, Direct transcriptional targets of sex steroid hormones in bone. J. Cell. Biochem. 112(2), 401\u2013408 (2011). doi: 10.1002\/jcb.22970","journal-title":"J. Cell. Biochem."},{"issue":"12","key":"83_CR42","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"S.L. Greenspan, P. Coates, S.M. Sereika, J.B. Nelson, D.L. Trump, N.M. Resnick, Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J. Clin. Endocrinol. Metab. 90(12), 6410\u20136417 (2005). doi: 10.1210\/jc.2005-0183","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"83_CR43","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1172\/JCI10942","volume":"106","author":"A Falahati-Nini","year":"2000","unstructured":"A. Falahati-Nini, B.L. Riggs, E.J. Atkinson, W.M. O\u2019Fallon, R. Eastell, S. Khosla, Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J. Clin. Invest. 106(12), 1553 (2000). doi: 10.1172\/JCI10942","journal-title":"J. Clin. Invest."},{"issue":"2","key":"83_CR44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11764-009-0114-1","volume":"4","author":"F Haseen","year":"2010","unstructured":"F. Haseen, L. Murray, C. Cardwell, J. O\u2019Sullivan, M. Cantwell, The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J. Cancer Surviv. Res. Pract. 4(2), 128\u2013139 (2010). doi: 10.1007\/s11764-009-0114-1","journal-title":"J. Cancer Surviv. Res. Pract."},{"issue":"3","key":"83_CR45","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.critrevonc.2006.06.006","volume":"60","author":"SMH Alibhai","year":"2006","unstructured":"S.M.H. Alibhai, S. Gogov, Z. Allibhai, Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit. Rev. Oncol. Hematol. 60(3), 201\u2013215 (2006). doi: 10.1016\/j.critrevonc.2006.06.006","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"83_CR46","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","volume":"87","author":"D Mittan","year":"2002","unstructured":"D. Mittan, S. Lee, E. Miller, R.C. Perez, J.W. Basler, J.M. Bruder, Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J. Clin. Endocrinol. Metab. 87(8), 3656\u20133661 (2002). doi: 10.1210\/jc.87.8.3656","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"83_CR47","doi-asserted-by":"crossref","first-page":"E456","DOI":"10.1210\/jc.2010-0902","volume":"95","author":"EJ Hamilton","year":"2010","unstructured":"E.J. Hamilton, A. Ghasem-Zadeh, E. Gianatti, D. Lim-Joon, D. Bolton, R. Zebaze, E. Seeman, J.D. Zajac, M. Grossmann, Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J. Clin. Endocrinol. Metab. 95(12), E456\u2013E463 (2010). doi: 10.1210\/jc.2010-0902","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"83_CR48","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/jbmr.405","volume":"26","author":"LJ Melton","year":"2011","unstructured":"L.J. Melton, M.M. Lieber, E.J. Atkinson, S.J. Achenbach, H. Zincke, T.M. Therneau, S. Khosla, Fracture risk in men with prostate cancer: a population-based study. J. Bone Miner. Res. 26(8), 1808\u20131815 (2011). doi: 10.1002\/jbmr.405","journal-title":"J. Bone Miner. Res."},{"issue":"31","key":"83_CR49","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","volume":"23","author":"MR Smith","year":"2005","unstructured":"M.R. Smith, W.C. Lee, J. Brandman, Q. Wang, M. Botteman, C.L. Pashos, Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J. Clin. Oncol. 23(31), 7897\u20137903 (2005). doi: 10.1200\/jco.2004.00.6908","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"83_CR50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF01623008","volume":"6","author":"D Gatti","year":"1996","unstructured":"D. Gatti, M. Rossini, N. Zamberlan, V. Braga, E. Fracassi, S. Adami, Effect of aging on trabecular and compact bone components of proximal and ultradistal radius. Osteoporosis Int. 6(5), 355\u2013360 (1996). doi: 10.1007\/BF01623008","journal-title":"Osteoporosis Int."},{"issue":"13","key":"83_CR51","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","volume":"345","author":"MR Smith","year":"2001","unstructured":"M.R. Smith, F.J. McGovern, A.L. Zietman, M.A. Fallon, D.L. Hayden, D.A. Schoenfeld, P.W. Kantoff, J.S. Finkelstein, Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 345(13), 948\u2013955 (2001). doi: 10.1056\/NEJMoa010845","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"83_CR52","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00198-006-0321-9","volume":"18","author":"AB Araujo","year":"2007","unstructured":"A.B. Araujo, T.G. Travison, S.S. Harris, M.F. Holick, A.K. Turner, J.B. McKinlay, Race\/ethnic differences in bone mineral density in men. Osteoporosis Int. 18(7), 943\u2013953 (2007). doi: 10.1007\/s00198-006-0321-9","journal-title":"Osteoporosis Int."},{"issue":"6","key":"83_CR53","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bone.2008.08.106","volume":"43","author":"EM Lewiecki","year":"2008","unstructured":"E.M. Lewiecki, C.M. Gordon, S. Baim, M.B. Leonard, N.J. Bishop, M.-L. Bianchi, H.J. Kalkwarf, C.B. Langman, H. Plotkin, F. Rauch, B.S. Zemel, N. Binkley, J.P. Bilezikian, D.L. Kendler, D.B. Hans, S. Silverman, International society for clinical densitometry 2007 adult and pediatric official positions. Bone 43(6), 1115\u20131121 (2008). doi: 10.1016\/j.bone.2008.08.106","journal-title":"Bone"},{"issue":"13","key":"83_CR54","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"F.H. Schr\u00f6der, J. Hugosson, M.J. Roobol, T.L.J. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan, H. Lilja, M. Zappa, L.J. Denis, F. Recker, A. Berenguer, L. M\u00e4\u00e4tt\u00e4nen, C.H. Bangma, G. Aus, A. Villers, X. Rebillard, T. van der Kwast, B.G. Blijenberg, S.M. Moss, H.J. de Koning, A. Auvinen, Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360(13), 1320\u20131328 (2009). doi: 10.1056\/NEJMoa0810084","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"83_CR55","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4103\/0970-1591.105750","volume":"28","author":"MR Pradhan","year":"2012","unstructured":"M.R. Pradhan, A. Mandhani, S.S. Chipde, A. Srivastava, M. Singh, R. Kapoor, Bone densitometric assessment and management of fracture risk in Indian men of prostate cancer on androgen deprivation therapy: does practice pattern match the guidelines? Indian J. Urol. 28(4), 399\u2013404 (2012). doi: 10.4103\/0970-1591.105750","journal-title":"Indian J. Urol."},{"issue":"2","key":"83_CR56","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cncr.20766","volume":"103","author":"T Tanvetyanon","year":"2005","unstructured":"T. Tanvetyanon, Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 103(2), 237\u2013241 (2005). doi: 10.1002\/cncr.20766","journal-title":"Cancer"},{"issue":"8","key":"83_CR57","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1464-410X.2012.11777.x","volume":"111","author":"M Nadler","year":"2013","unstructured":"M. Nadler, S. Alibhai, P. Catton, C. Catton, M.J. To, J.M. Jones, Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 111(8), 1301\u20131309 (2013). doi: 10.1111\/j.1464-410X.2012.11777.x","journal-title":"BJU Int."},{"issue":"3","key":"83_CR58","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jama.2011.2022","volume":"307","author":"SM Alibhai","year":"2012","unstructured":"S.M. Alibhai, L. Yun, A.M. Cheung, L. Paszat, Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA 307(3), 255\u2013256 (2012)","journal-title":"JAMA"},{"key":"83_CR59","unstructured":"National comprehensive cancer network: NCCN guidelines for prostate cancer (version 2.2013) (2013), http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf . Accessed 6 June 2013"},{"issue":"1","key":"83_CR60","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12020-012-9696-x","volume":"42","author":"K Sinningen","year":"2012","unstructured":"K. Sinningen, E. Tsourdi, M. Rauner, T. Rachner, C. Hamann, L. Hofbauer, Skeletal and extraskeletal actions of denosumab. Endocrine 42(1), 52\u201362 (2012). doi: 10.1007\/s12020-012-9696-x","journal-title":"Endocrine"},{"issue":"1","key":"83_CR61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12020-013-9880-7","volume":"44","author":"R Adler","year":"2013","unstructured":"R. Adler, Osteoporosis in men: recent progress. Endocrine 44(1), 40\u201346 (2013). doi: 10.1007\/s12020-013-9880-7","journal-title":"Endocrine"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-013-0083-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-013-0083-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-013-0083-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:01:12Z","timestamp":1596758472000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-013-0083-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,31]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["83"],"URL":"https:\/\/doi.org\/10.1007\/s12020-013-0083-z","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,31]]}}}